Breaking News Headlines Today

News from curetoday.com

See all of curetoday.com news coverage in one place. Discover how curetoday.com’s media bias informs their coverage and compare with thousands of other news outlets.

We’ve discovered 402 headlines written by curetoday.com during the past 3 months.

We’ve assigned a media bias rating of unknown to curetoday.com. You can read more about our methodology here.

curetoday.com’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about curetoday.com

Where is curetoday.com located?curetoday.com's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top curetoday.com News

Pharma · United States

Top German Pharma Boehringer Wins US Approval for Cancer Drug

67% Center coverage: 3 sources

Boehringer Ingelheim GmbH won approval in the U.S. for its drug to treat a challenging form of lung cancer, offering a growth avenue for the privately-held German pharmaceuticals company.See the Story

Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79% - Genmab (NASDAQ:GMAB)

100% Center coverage: 1 sources

Genmab A/S (NASDAQ:GMAB) released results Thursday of the Phase 3 EPCORE FL-1 trial evaluating subcutaneous epcoritamab in combination with rituximab and lenalidomide (R2) versus R2 alone for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The study met its dual primary endpoints of overall response rate (ORR) and progression-free survival (PFS), demonstrating statistically significant and clinically meaningful differe…See the Story

Medical · Buffalo

Genomics-Guided Tool Helps Guide Immunotherapy Choices for Advanced Kidney Cancers

100% Center coverage: 1 sources

A study led by Roswell Park Comprehensive Cancer Center helps explain why a rare and hyper-aggressive subtype of kidney cancer is susceptible to immunotherapy—information that helped researchers create a first-of-its-kind tool to guide treatment decisions for advanced kidney cancers.See the Story

CLL: More Protection, More Problems?

Immunoglobulin replacement therapy shows limited benefit for preventing infection in chronic lymphocytic leukemia. Medscape Medical NewsMedical See the Story

Anbogen Receives FDA Clearance to Initiate Phase 1/2 Trial of ABT-301 Triplet Therapy for Advanced Colorectal Cancer

TAIPEI, Aug. 4, 2025 /PRNewswire/ — Anbogen Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for ABT-301, enabling the initiation of a Phase 1/2 clinical trial in combination with tislelizumab and bevacizumab for patients with metastatic colorectal cancer (mCRC). This open-label, multi-center international study […] The post Anbogen Receives FDA Clearance to…Cancer · United States See the Story

News from curetoday.com

News from curetoday.com

Information about curetoday.com

Media Bias Ratings

Factuality

Ownership

Top curetoday.com News

Top German Pharma Boehringer Wins US Approval for Cancer Drug

Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79% - Genmab (NASDAQ:GMAB)

Genomics-Guided Tool Helps Guide Immunotherapy Choices for Advanced Kidney Cancers

CLL: More Protection, More Problems?

Anbogen Receives FDA Clearance to Initiate Phase 1/2 Trial of ABT-301 Triplet Therapy for Advanced Colorectal Cancer

New Clinical Trials Launch as Cancer Treatment Studies Advance

Using Social Media to Amplify the Patient Voice and Advocacy

Incidence of Early-Onset Liver Cancer in Younger Patients Decreasing

Please Don’t Call Me ‘Dear’: A Poem From Cancer Treatment

Survivorship Anxiety: What Comes After Cancer Treatment

Mom Supports Other Parents After Daughter’s Bone Cancer Diagnosis

Similar News Topics

Topics Most Covered by curetoday.com

Sources Covering Similar Topics

Breaking News Topics Related to curetoday.com

Information about curetoday.com

Media Bias Ratings

Factuality

Ownership

CLL: More Protection, More Problems?

Anbogen Receives FDA Clearance to Initiate Phase 1/2 Trial of ABT-301 Triplet Therapy for Advanced Colorectal Cancer

New Clinical Trials Launch as Cancer Treatment Studies Advance

Using Social Media to Amplify the Patient Voice and Advocacy

Incidence of Early-Onset Liver Cancer in Younger Patients Decreasing

Please Don’t Call Me ‘Dear’: A Poem From Cancer Treatment

Survivorship Anxiety: What Comes After Cancer Treatment

Mom Supports Other Parents After Daughter’s Bone Cancer Diagnosis